This viewpoint discusses the importance of evidence-based labeling for hormone replacement therapy products, highlighting risks and benefits.
This Viewpoint discusses weighing the evidence of benefits and risks of various estrogen products following the US Food and Drug Administration’s decision to remove most box warnings from hormone replacement therapy products.
No takes yet. Share an insight, caveat, or question.
Wittes et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: